Preclinical studies showed that GD2‐B7H395 or ROR1‐B7H396 synNotch CAR‐T cells significantly killed tumor cells with high specificity and efficacy and without toxicity to normal cells expressing the target antigen. This evidence concerns the gene ROR1 and neoplasm.